Last reviewed · How we verify
NCT03684395
Accessibility to New Drugs Versus SOC in Sweden
trial testing DOACs: Rivaroxaban, Dabigatran, Apixaban in Anticoagulation in 68,056 participants. Completed in 30 June 2017.
30 June 2017
Quick facts
| Lead sponsor | Bayer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 68,056 |
| Start date | 15 June 2016 |
| Primary completion | 30 June 2017 |
| Estimated completion | 30 June 2017 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- DOACs: Rivaroxaban, Dabigatran, Apixaban — full drug profile →
- Standard of care (Warfarin) — full drug profile →
Conditions studied
- Anticoagulation — all drugs for Anticoagulation →
Sponsor
Bayer — full company profile →
Who can join
18 and older, any sex, with Anticoagulation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment. Socioeconomic disparities have been shown to influence patient management and health outcomes in certain Swedish populations. The Swedish Board of Health and Welfare has stated that the prescription of new drugs, which are more expensive than generic standard of care drugs, might be influenced by patients' socioeconomic status. To evaluate the association between socioeconomic factors and use of a DOAC (rivaroxaban, dabigatran, or apixaban) or standard of care (warfarin) in patients with NVAF in Sweden.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03684395
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anticoagulation
Currently open trials in the same condition.
- NCT05782270 — Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy · Phase 4 · recruiting
- NCT07129395 — Anticoagulation Adherence Measurement Strategies · active not recruiting
- NCT04539301 — Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux L · recruiting
- NCT03910933 — Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative · active not recruiting
Other Bayer trials
Trials by the same sponsor.
- NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
- NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
- NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03684395 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayer
- Last refreshed: 29 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684395.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing